FI89240B - Anvaendning av tillsatsmedel foer oekning av ibuprofens absorptionshastighet - Google Patents
Anvaendning av tillsatsmedel foer oekning av ibuprofens absorptionshastighet Download PDFInfo
- Publication number
- FI89240B FI89240B FI906237A FI906237A FI89240B FI 89240 B FI89240 B FI 89240B FI 906237 A FI906237 A FI 906237A FI 906237 A FI906237 A FI 906237A FI 89240 B FI89240 B FI 89240B
- Authority
- FI
- Finland
- Prior art keywords
- ibuprofen
- absorption
- absorption rate
- increasing
- additive
- Prior art date
Links
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 17
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229960001680 ibuprofen Drugs 0.000 title claims abstract description 15
- 239000000654 additive Substances 0.000 title description 3
- 230000000996 additive effect Effects 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims description 7
- 229940126701 oral medication Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract description 3
- 239000000347 magnesium hydroxide Substances 0.000 abstract description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 13
- 239000000395 magnesium oxide Substances 0.000 description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 7
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 239000008279 sol Substances 0.000 description 6
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Small-Scale Networks (AREA)
- Exhaust-Gas Circulating Devices (AREA)
- Automatic Tape Cassette Changers (AREA)
Claims (1)
- 5 89240 Patenttivaatimus Mg(OH)2:n ja/tai MgO:n käyttö oraalisissa lääkevalmisteis-5 sa, kuten tableteissa, ibuprofeenin imeytymisnopeuden lisäämiseksi. 10 Användning av Mg(OH)2 och/eller MgO i orala 1äkemedelspre-parat, säsom tabletter, för att öka absorptionshastigheten för ibuprofen. 15
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI880712 | 1988-02-16 | ||
| FI880712A FI89004C (sv) | 1988-02-16 | 1988-02-16 | Användning av tillsatsmedel för ökning av absorptionshastigheten av lä kemedel i orala läkemedelspreparat |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI906237A0 FI906237A0 (fi) | 1990-12-18 |
| FI89240B true FI89240B (fi) | 1993-05-31 |
| FI89240C FI89240C (sv) | 1993-09-10 |
Family
ID=8525923
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI880712A FI89004C (sv) | 1988-02-16 | 1988-02-16 | Användning av tillsatsmedel för ökning av absorptionshastigheten av lä kemedel i orala läkemedelspreparat |
| FI906237A FI89240C (sv) | 1988-02-16 | 1990-12-18 | Användning av tillsatsmedel för ökning av ibuprofens absorptionshastig het |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI880712A FI89004C (sv) | 1988-02-16 | 1988-02-16 | Användning av tillsatsmedel för ökning av absorptionshastigheten av lä kemedel i orala läkemedelspreparat |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0414688B1 (sv) |
| AT (1) | ATE110266T1 (sv) |
| AU (1) | AU3062389A (sv) |
| DE (1) | DE68917727T2 (sv) |
| FI (2) | FI89004C (sv) |
| WO (1) | WO1989007439A1 (sv) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533162A1 (de) * | 1995-09-08 | 1997-03-13 | Bayer Ag | Pharmazeutisches Kombinationspräparat mit Ketoprofen |
| TW430561B (en) * | 1995-12-20 | 2001-04-21 | Gea Farmaceutisk Fabrik As | Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet |
| PT2559430E (pt) | 2005-03-22 | 2015-10-09 | Stada Arzneimittel Ag | Ibuprofeno solubilizado |
| EP1800667A1 (en) | 2005-12-23 | 2007-06-27 | Losan Pharma GmbH | Rapidly solubilizing ibuprofen granulate |
| US11135188B2 (en) | 2009-05-11 | 2021-10-05 | Bayer Healthcare Llc | Method and composition to improve absorption of therapeutic agents |
| JP2014098009A (ja) * | 2014-01-29 | 2014-05-29 | Ss Pharmaceut Co Ltd | 経口用イブプロフェン製剤 |
| MX2023005639A (es) | 2020-11-13 | 2023-09-22 | Bayer Healthcare Llc | Comprimidos de capa doble orales que comprenden acido acetilsalicilico y pseudoefedrina, metodos para preparar y utilizar los mismos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217340A (en) * | 1979-03-21 | 1980-08-12 | Merck & Co., Inc. | Rapid acting combination of phenyl benzoic acid compounds and magnesium hydroxide |
| US4294819A (en) * | 1980-08-18 | 1981-10-13 | Bristol-Myers Company | Alkaline analgesic capsule |
| DE3151196A1 (de) * | 1981-12-23 | 1983-06-30 | Kurt Heinz Prof. Dr. 7800 Freiburg Bauer | Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen |
| CA1234761A (en) * | 1984-08-10 | 1988-04-05 | Herbert Lapidus | Chewable aspirin and buffering material tablet and method for producing same |
-
1988
- 1988-02-16 FI FI880712A patent/FI89004C/sv not_active IP Right Cessation
-
1989
- 1989-02-15 WO PCT/FI1989/000024 patent/WO1989007439A1/en not_active Ceased
- 1989-02-15 EP EP89902387A patent/EP0414688B1/en not_active Expired - Lifetime
- 1989-02-15 AU AU30623/89A patent/AU3062389A/en not_active Abandoned
- 1989-02-15 DE DE68917727T patent/DE68917727T2/de not_active Expired - Fee Related
- 1989-02-15 AT AT89902387T patent/ATE110266T1/de not_active IP Right Cessation
-
1990
- 1990-12-18 FI FI906237A patent/FI89240C/sv active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP0414688A1 (en) | 1991-03-06 |
| AU3062389A (en) | 1989-09-06 |
| DE68917727T2 (de) | 1995-04-06 |
| FI89240C (sv) | 1993-09-10 |
| WO1989007439A1 (en) | 1989-08-24 |
| FI906237A0 (fi) | 1990-12-18 |
| FI89004C (sv) | 1993-08-10 |
| DE68917727D1 (de) | 1994-09-29 |
| FI89004B (fi) | 1993-04-30 |
| FI880712A0 (fi) | 1988-02-16 |
| ATE110266T1 (de) | 1994-09-15 |
| FI880712L (fi) | 1989-08-17 |
| EP0414688B1 (en) | 1994-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0163723B1 (en) | Ddavp antidiuretic and method therefor | |
| EP0011489B1 (en) | An analgesic effervescent powder and process for its preparation | |
| JP3121080B2 (ja) | カプセル封入用溶液 | |
| RU2153337C2 (ru) | Таблетка парацетамола и домперидона с пленочным покрытием | |
| JP3667381B2 (ja) | 解熱鎮痛剤 | |
| KR870009717A (ko) | 신규 경구용 약제 | |
| JP3038456B2 (ja) | ジデオキシプリンヌクレオシドの改良された経口投与処方物 | |
| JPH05186332A (ja) | 少なくとも２種の異なる作用物質を備えた薬剤学的製剤の製造方法と使用 | |
| HU224983B1 (en) | Swallow tablet comprising paracetamol | |
| FI89240B (fi) | Anvaendning av tillsatsmedel foer oekning av ibuprofens absorptionshastighet | |
| US4387093A (en) | Arthritis treatment | |
| HUP0400127A2 (hu) | Paracetamolt tartalmazó lenyelhető tabletta | |
| JP3170855B2 (ja) | イブプロフェン含有解熱鎮痛剤 | |
| JPH05148139A (ja) | イブプロフエン含有解熱鎮痛剤 | |
| CA1182049A (en) | Apap antacid composition | |
| SU1009467A1 (ru) | Средство дл растворени мочевых конкрементов | |
| UA73316C2 (uk) | Фармацевтичний засіб, що містить похідну бензаміду як активний інгредієнт | |
| JPS5938203B2 (ja) | 補酵素ｑを主成分とする脳循環障害治療剤 | |
| JPH0140009B2 (sv) | ||
| US5091191A (en) | Pharmaceutical composition with improved dissolution property | |
| RU2192248C2 (ru) | Препарат "антигриппин" | |
| AU2004251439A1 (en) | Tablet comprising fluvastatin and carmellose calcium | |
| GB2174004A (en) | Effervescent tablets | |
| EP0067136B1 (en) | Pharmaceutical composition of phosphonomicin in tablet form | |
| RU2422145C2 (ru) | Комбинированная противотуберкулезная фармацевтическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| FG | Patent granted |
Owner name: NEUVONEN, PERTTI J. |